07/01/2019
EQS-News

Zur Rose Group: Acquisition of medpex successfully concluded

EQS Group-News: Zur Rose Group AG / Key word(s): Mergers & Acquisitions

07.01.2019 / 07:00


Press release

Zur Rose Group: Acquisition of medpex successfully concluded

The Zur Rose Group has successfully completed the acquisition of the e-commerce activities of Germany's third-largest online pharmacy medpex. In the course of this transaction, the Group acquired Comventure GmbH in Forst (Germany), Visionrunner GmbH in Mannheim (Germany), medpex wholesale GmbH in Ludwigshafen (Germany), as well as Apotheke esando B.V. in Venlo (Netherlands). With this step, the Zur Rose Group is significantly expanding its market leadership in Germany.

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Pascale Ineichen, spokesperson
Email: media@zurrose.com, phone: +41 52 724 08 18

Financial Calendar
23 January 2019 Sales 2018
21 March 2019 Annual Results 2018
17 April 2019 Q1/2019 Trading Update
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest online pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.

The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,000 people at various locations and generated a turnover of CHF 983 million in the 2017 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com



End of Corporate News



show this
Media Release (PDF)
Zur Rose Group
06/04/2022
Ad hoc News

Zur Rose Group AG publishes invitation to the Annual General Meeting of 28 April 2022

Read more
Max Müller to
28/03/2022
Corporate News

Max Müller to be new CEO of TeleClinic, taking over from founder and former CEO Katharina Jünger

Read more
Zur Rose Group:
24/03/2022
Ad hoc News

Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued

Read more
Zur Rose Group:
20/01/2022
Corporate News

Zur Rose Group: steady growth in a volatile market environment

Read more
Zur Rose Group
10/01/2022
Corporate News

Zur Rose Group nominates Rongrong Hu as director

Read more
Zur Rose and
16/12/2021
Corporate News

Zur Rose and the Swiss Association for the Blind and Visually Impaired make it easier for people with a visual impairment to take medication

Read more
01/06